High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients

High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients

The diagnosis and classification of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is essential to improve the prognosis of systemic sclerosis (SSc) patients. The risk-stratification of disease severity and follow-up requires a multidisciplinary approach, integrating high-resoluti...

Full description

Bibliographic Details
Main Authors:	Barbara Ruaro, Elisa Baratella, Paola Confalonieri, Barbara Wade, Cristina Marrocchio, Pietro Geri, Annalisa Busca, Riccardo Pozzan, Alessia Giovanna Andrisano, Maria Assunta Cova, Marco Confalonieri, Francesco Salton
Format:	Article
Language:	English
Published:	MDPI AG 2021-10-01
Series:	Diagnostics
Subjects:	systemic sclerosis-associated interstitial lung disease (SSc-ILD) interstitial lung disease (ILD) systemic sclerosis (SSc) high-resolution computed tomography (HRTC) pulmonary function tests (PFT) usual interstitial pneumonia (UIP)
Online Access:	https://www.mdpi.com/2075-4418/11/11/1960

Similar Items

High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose?
by: Barbara Ruaro, et al.
Published: (2021-12-01)

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
by: Toshiyuki Sumi, et al.
Published: (2021-03-01)

Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy
by: Barbara Ruaro, et al.
Published: (2023-02-01)

The diagnostic trajectories of Danish patients with autoimmune rheumatologic disease associated interstitial lung disease: an interview-based study
by: MB Johansen, et al.
Published: (2023-01-01)

Influence of CT Image Matrix Size and Kernel Type on the Assessment of HRCT in Patients with SSC-ILD
by: Bettina D. Balmer, et al.
Published: (2022-07-01)

Nintedanib in systemic sclerosis treatment: a case report
by: Maysoun Kudsi, et al.
Published: (2024-02-01)

Safety of prolonged use of metoclopramide and domperidone as treatment for chronic gastrointestinal dysmotility disorders in patients with systemic sclerosis
by: Saad Alkhowaiter, et al.
Published: (2024-05-01)

Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis
by: Rajesh Swarnakar, et al.
Published: (2022-01-01)

Clinical Characterization and Predictive Factors for Progression in a Cohort of Patients with Interstitial Lung Disease and Features of Autoimmunity: The Need for a Revision of IPAF Classification Criteria
by: Francesco Bozzao, et al.
Published: (2023-04-01)

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?
by: Barbara Ruaro, et al.
Published: (2022-08-01)

Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study
by: Barbara Ruaro, et al.
Published: (2024-01-01)

Egyptian evidence-based consensus on clinical practice recommendations for the management of systemic sclerosis
by: Yasser El Miedany, et al.
Published: (2024-02-01)

Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study
by: Patrycja Rzepka-Wrona, et al.
Published: (2022-12-01)

Smoking Related Interstitial Lung Disease - High Resolution Computed Tomography (HRCT) findings in 40 smokers
by: Youssriah Yahia Sabri, et al.
Published: (2014-06-01)

The Patterns of pulmonary manifestations in ILDs in rheumatoid arthritis
by: Wael Abdelmohsen Abo zaid, et al.
Published: (2022-07-01)

The Role of Autophagy and Apoptosis in Affected Skin and Lungs in Patients with Systemic Sclerosis
by: Vesna Spasovski, et al.
Published: (2023-07-01)

Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience
by: Maria Boutel, et al.
Published: (2023-03-01)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021-08-01)

Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study
by: Kyung-In Joung, et al.
Published: (2023-03-01)

A Cross-Sectional Survey of Pulmonologists Working at Non-ILD Centers in the United States
by: Biehl R, et al.
Published: (2023-07-01)

Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial
by: Matthias Griese, et al.
Published: (2020-04-01)

Changes in peripheral T-lymphocyte subsets and serum cytokines in patients with systemic sclerosis
by: Rong-Hong Guo, et al.
Published: (2022-11-01)

Transbronchial lung cryobiopsy and pulmonary fibrosis: A never-ending story?
by: Barbara Ruaro, et al.
Published: (2023-04-01)

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
by: Anna-Maria Hoffmann-Vold, et al.
Published: (2020-07-01)

Complications in Idiopathic Pulmonary Fibrosis: Focus on Their Clinical and Radiological Features
by: Federica Galioto, et al.
Published: (2020-07-01)

Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ?
by: Julien Guiot, et al.
Published: (2022-04-01)

Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review
by: Marvin J. Fritzler, et al.
Published: (2023-03-01)

Editorial: Pulmonary fibrosis: One manifestation, various diseases
by: Barbara Ruaro, et al.
Published: (2022-10-01)

The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: A retrospective and prospective study
by: Yuxue Chen, et al.
Published: (2022-09-01)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
by: Elisabetta Zanatta, et al.
Published: (2023-05-01)

Cystic lung lesion following transbronchial lung cryobiopsy: Case report and systematic review
by: Srikant Kashinath Malegaonkar, et al.
Published: (2023-01-01)

Role of IOS in evaluation of patients with interstitial lung diseases
by: B.A. Naglaa, et al.
Published: (2016-10-01)

Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese Rheumatism Data Center
by: Haoguang Li, et al.
Published: (2022-12-01)

Childhood interstitial lung disease: When to suspect and what to do
by: Grazia Fenu, et al.
Published: (2024-06-01)

Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosisResearch in context
by: Theresia A. Mikolasch, et al.
Published: (2023-01-01)

The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis
by: Isabella M. Atzeni, et al.
Published: (2023-06-01)

Bridges of Pulmonology 2023 proceedings: Highlights in the field of interstitial lung diseases
by: Vasilina Sotiropoulou, et al.
Published: (2024-03-01)

Etiologic Classification of Diffuse Parenchymal (Interstitial) Lung Diseases
by: Matthias Griese
Published: (2022-03-01)

Hook effect and serum KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
by: Emmy Hermiyanti Pranggono, et al.
Published: (2021-10-01)

Correlation between Microvascular Damage and Internal Organ Involvement in Scleroderma: Focus on Lung Damage and Endothelial Dysfunction
by: Mario D’Oria, et al.
Published: (2022-12-01)